CHARLOTTESVILLE, Va.--(BUSINESS WIRE)--Tau Therapeutics LLC announced that founder Dr. Timothy Macdonald will be honored at Virginia Bio’s 20th Anniversary Celebration in Charlottesville on May 2nd. Virginia Bio selected Dr. Macdonald as one of 20 awardees recognized for exemplary contributions to biotechnology within the Commonwealth and beyond.
“Dr. Macdonald is a very worthy recipient of this honor,” said Andrew Krouse, President and CEO of Tau Therapeutics. “He possesses a rare combination of innovative genius, business acumen and the ability to connect and succeed in both academia and industry.”
Dr. Macdonald has contributed to Virginia biotech research, development and commercialization for 30 years as Professor of Chemistry and Pharmacology at the University of Virginia. He has founded six Virginia pharmaceutical companies. Dr. Macdonald has shepherded four of his own compounds from the bench to the clinic and helped to oversee development of another dozen drugs as an industry consultant, including as senior scientific advisor to Allergan, Inc. The UVA Patent Foundation has twice honored Dr. Macdonald as the Edlich-Henderson Inventor of the Year for research of notable value to society. Dr. Macdonald is an expert in the creation of T-type calcium channel blockers for use in cancer. He has over 250 publications and 45 pending and issued patents. His influence on the biotech community continues to spread as approximately 80% of his postgraduate students have continued their careers as pharmaceutical industry leaders.
About Tau Therapeutics LLC
Tau Therapeutics, a privately held oncology company based in Charlottesville, VA, is at the forefront of cancer research focusing on controlling the proliferation pathway. Tau’s Interlaced Therapy™ is built on the rationale that using a T-type calcium channel inhibitor to increase the proportion of cancer cells and cancer stem cells at the point of maximum metabolic vulnerability in S phase will increase cell death caused by chemotherapies. By more effectively reducing tumor burden and killing the cells that cause recurrence, Tau believes it will offer a significant advancement in cancer treatment.
Forward-Looking Statement
This press release contains forward-looking statements that are subject to risks and uncertainties, and includes statements that are not historical facts. Actual results could differ significantly from results discussed. Tau Therapeutics LLC disclaims any intent or obligation to update forward-looking statements, except as required by law.
